Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Subscribe To Our Newsletter & Stay Updated
